PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70532 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Daniel Q Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Lipase, Membrane Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background and Aims PNPLA3 variants are associated with increased hepatocellular carcinoma (HCC) risk. We examined the association between a combination of the PNPLA3 I148M genotype and clinical risk factors with HCC risk using data from a large, ongoing, population‐based, prospective cohort study, the Singapore Chinese Health Study. Approach and Results This study included 24,979 participants (54.2% female). The primary outcome was incident HCC. Fine‐Grey models were used to examine the association between a combination of the PNPLA3 I148M genotype and clinical risk factors and risk of HCC. After a median follow‐up of 19.8 years, we identified 214 HCC incident cases. Males who were homozygous carriers for PNPLA3 I148M (adjusted hazard ratio [aHR] = 9.23, 95% confidence interval [CI]: 4.81–17.70) had a nine‐fold risk of HCC, while heterozygous male carriers (aHR 4.83, CI: 2.63–8.89) had a five‐fold risk of HCC, compared to non‐carrier females. Homozygous carriers who were overweight (aHR = 2.92, 95% CI: 1.74–4.89) had a three‐fold risk of HCC compared to non‐carriers who were not overweight. Participants with diabetes and who were homozygous carriers (aHR 2.83, 95% CI: 1.21–6.61) had an approximately three‐fold risk of HCC compared to non‐carriers without diabetes. Conclusion The frequency of rs738409‐G alleles was associated with a dose‐dependent increase in HCC risk and was independent of other clinical risk factors. Among participants who were male, overweight, and those with diabetes, the risk of HCC was further elevated among those with rs738409‐G alleles. These data may be helpful for the development of future risk stratification strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore.
- Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Daniel Q Huang, Rajkumar Dorajoo
Förderung
- NCI NIH HHS
Zitieren
APA
Huang, D. Q., Zhang, Z., Dorajoo, R., Khor, C. C., Pham, Y. T., Wang, R., Behari, J., Yuan, J. M., Koh, W. P., & Luu, H. N. (2026). PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70532
Vancouver
Huang DQ, Zhang Z, Dorajoo R, Khor CC, Pham YT, Wang R, et al. PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70532
BibTeX
@article{Huang2026,
author = {Huang, Daniel Q and Zhang, Zhongjie and Dorajoo, Rajkumar and Khor, Chiea Chuen and Pham, Yen Thi-Hai and Wang, Renwei and Behari, Jaideep and Yuan, Jian-Min and Koh, Woon-Puay and Luu, Hung N},
title = {PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70532}
}
EUVIMED